Insulin-like growth factor binding protein 4 (IGFBP4/ BP4) gene expression plays an important role in the transition from proliferation to differentiation of a human colon cancer cell line, CaCo2. We recently cloned and identified multiple cis elements (including putative binding sites for activator protein 1 (AP-1) and specificity proteins (Sps) ) in the promoter of human BP4 gene, and measured a significant upregulation of the promoter activity in response to c-Jun. We therefore examined the role of the single AP-1 site (À869/À863) and other cis elements, in regulating the expression of hBP4 gene, in the current studies. Deletion of a 25 bp sequence from À872 to À848, which contains the AP-1 site, significantly reduced BP4 promoter activity by approximately 50%. Surprisingly, mutation of the AP-1 site did not produce significant alteration in the activity of the BP4 promoter. However, mutation of 7 bp (5 0 -TGCTGCA) at the 3 0 end of the AP-1 site resulted in significantly decreasing the promoter activity by 450%. Proteins bound to the 25 bp probe (À872/À848) could be supershifted by antibodies specific for JunD and Sp3 in an EMSA. JunD binding was abolished on mutation of the AP-1 site and Sp3 binding was abolished on mutation of the 7 bp at À861/À855; binding of the purified Sp3 protein to the 25 bp probe was similarly abolished on mutation of the newly discovered Sp3 binding site (TGCTGCA). BP4 promoter activity was upregulated in insect cells in response to Sp3 expression, confirming a functional importance of the novel Sp3 binding site. These studies suggest that the Sp3 binding site, rather than the AP-1 site, may be playing a significant role in regulating the expression of IGFBP4 gene in CaCo2 cells.
Introduction
Several insulin-like growth factor binding proteins (IGFBPs) have been identified and cloned to date (Shimasaki and Ling, 1991; Singh, 2000) . Most human colon cancers express IGFBP2 and IGFBP4, and o50% also express IGFBP3, IGFBP5 and/or IGFBP6; none express IGFBP1 (Singh et al., 1994b; Park et al., 1996) . IGFBPs play an important role in modulating the mitogenic effects of insulin-like growth factors (IGFs) (Jones and Clemmons, 1995; Singh, 2000) . Both inhibitory and stimulatory effects of IGFBP proteins have been reported (De Mellow and Baxter, 1988; Singh et al., 1994a; Jones and Clemmons, 1995; Mohan et al., 1995; Huynh et al., 1996; Duan and Clemmons, 1998; Singh, 2000) . Inhibitory effects are primarily attributed to competitive scavenging of the IGFs away from IGF-I-R (Jones and Clemmons, 1995; Singh, 2000) . The expression and secretion of inhibitory IGFBPs (including BP4 (insulin-like growth factor binding proteins 4)) is significantly upregulated in differentiating cells (Singh, 2000) . Reports to date suggest that BP4 primarily functions as an inhibitory protein for colon cancer cells (Singh and Rubin, 1993; Oguchi et al., 1994; Singh et al., 1994a, b; Singh et al., 1996; Singh, 2000) . Differential expression of IGF-II and BP4 plays an important role in proliferation and differentiation of a human colon cancer cell line (CaCo2), which undergoes spontaneous enterocytic differentiation in culture (Oguchi et al., 1994; Singh et al., 1994b Singh et al., , 1996 Park et al., 1996; Zarrilli et al., 1999; Singh, 2000) . Differentiation of CaCo2 cells requires an attenuation of IGF-II effects (Singh et al., 1996; Zarrilli et al., 1999) , which is achieved by both a downregulation of IGF-II expression (Park et al., 1996; Zarrilli et al., 1999; Singh, 2000) and an upregulation of BP4 RNA (Oguchi et al., 1994; Park et al., 1996; Singh et al., 1996) . Mechanisms that mediate upregulation of BP4 mRNA in cancer cells, however, are unknown.
Cellular levels of IGFBPs can be potentially regulated at transcriptional and post-translational levels (Jones and Clemmons 1995) . BP4 is proteolytically degraded in several cell types (Conover et al., 1995; Miyakoshi et al., 2001; Smith et al., 2001; Zhang et al., 2002 ). Yet, evidence to date suggests that IGFBPs secreted by colon cancer cells are not subjected to proteolytic degradation (Singh 2000) . Levels of BP4 protein reflect levels of BP4 mRNA during growth and differentiation of CaCo2 cells (Oguchi et al., 1994; Park et al., 1996; Singh et al., 1996) , strongly suggesting that BP4 is regulated at the transcriptional level in CaCo2 cells. We cloned the 1.3 kb 5 0 flanking region of BP4 gene that contains all the cis elements required for regulating the BP4 gene in a cell-density-dependent manner in CaCo2 cells (Dai et al., 1997) . Several putative binding sites were identified in the regulatory region of BP4 gene, including sites for AP-1, Sp1 (Sp, specifity proteins), EGR1, WT1 and several other factors (Dai et al., 1997; Qin et al., 1997; Zazzi et al., 1998) . In parallel studies, we observed that the activity of the BP4 promoter-reporter was significantly increased in CaCo2 cells overexpressing c-Jun, while overexpression of EGR1 and WT-1 had no effect (Shen et al., 1998b) . Recent reports suggest that Sp1/3 proteins are importantly involved in regulating IGFBP1, IGFBP2 and IGFBP3 expression (Gao and Tseng 1996; Tseng et al., 1997) . The current study was therefore undertaken to examine possible functional roles of the single AP-1 binding site (À869/À863) and Sp1/3 site(s) in regulating the BP4 promoter activity in CaCo2 cells. Our current studies suggest that a novel Sp3 binding site in the distal segment of the functional hBP4 promoter, and Sp3 proteins play a critical role in upregulating BP4 promoter activity in CaCo2 cells.
Results

The human BP4 promoter sequence in reporter vector
The cloned full-length BP4 promoter in pGL-2 Basic luciferase (luc) reporter vector (Dai et al., 1997) was sequenced to facilitate the subsequent subcloning work. Differences in the nucleotide sequence, in comparison to our previously published sequence (Dai et al., 1997) , are noted in Table 1 . Total length of the functional promoter fragment that was finally cloned in the reporter vector was 1303 bp (À1250/ þ 52). Several DNA motifs were identified by Gene Tool software (BioTools Inc, Edmonton, Alberta, Canada) that are schematically presented in Figure 1a , and listed in Table 2 .
The BP4 (À1250/ þ 52)-luc vector retains all the functional elements
To confirm that the BP4 (À1250/ þ 52)-luc vector retained all the functional characteristics of the slightly longer promoter-luc vector used by us in previous studies (Dai et al., 1997) , we examined the promoter activity of BP4 (À1250/ þ 52)-luc in CaCo2 cells on different days of cell culture as previously described (Dai et al., 1997) . Transcriptional activity was upregulated rapidly and significantly (Po0.05) by days 5-7 in cell culture after plating, by 2-3 Â , compared to that on day 3, followed by a gradual decline on days 9-12. The pattern of promoter activity of BP4 (À1250/ þ 52)-luc vector was very similar to that previously reported by us for the longer construct (À1250/ þ 216) (Dai et al., 1997) , indicating that all the cis elements required for the density-dependent regulation of the promoter activity were retained in the BP4 (À1250/ þ 52)-luc promoter fragment.
Deletion of 50 bp of the promoter sequence (À897/À848) reduces the BP4 promoter activity by X50% in CaCo2 cells
We transfected CaCo2 cells on day 7, since BP4 expression reaches peak levels by day 7 (Singh et al., 1996) . Deletion from À897 to À848 resulted in a sharp and significant decline in the promoter activity (X50%, Figure 1b ), confirming the presence of positive regulatory element(s) in this fragment. Since the 50 bp sequence from À897 to À848 contains the consensus AP-1 site at À869/À863, it suggested that the AP-1 binding site may be involved in increasing the transcriptional activity of the BP4 promoter.
The 50 bp sequence (À897/À848) contains critical regulatory element other than AP-1 site
To validate the functional importance of the 50 bp fragment (À897/À848) in the BP4 promoter, this fragment was ligated back to the BP4 (À847/ þ 52)-luc vector. Addition of the 50 bp fragment to the 5 0 end of BP4 (À847/ þ 52)-luc vector resulted in restoring the promoter activity, equivalent to that of the wild-type (wt) construct BP4 (À897/ þ 52)-luc vector on days 6 and 8 (Figure 1c) . To determine the functional role of the AP-1 site, besides ligating back the 50 bp wt fragment, we also ligated back a mutant 50 bp fragment, which was mutated for the entire nucleotide (nt) sequence at the AP-1 site. Addition of the AP-1 mutant 50 bp fragment resulted in an almost complete recovery of the promoter activity (Figure 1c) , suggesting that the AP-1 consensus binding site present within the 50 bp regulatory fragment (À897/À848) was not directly involved in the regulation of the BP4 promoter activity. The promoter activity of the full-length (À1252/ þ 52) Table 1 Differences in the sequence of the IGFBP4 promoter (À1250/ +52) cloned in the pGL-2 luciferase reporter vector in the current study compared to that reported previously by us (Dai et al., 1997) Changes relative to the published sequence Position in the sequence
Between À956 and À955, +44 and +45 G Missing Between À875 and À874, À469 and À468 C and T reverse order À872 and À871 Exchange of T and A in complementary strand
À855
Sequencing was performed by ABI Prism Model 310. Changes in nt sequences compared to the sequence published by our laboratory previously (Dai et al., 1997) are shown. Consensus binding sites for AP-1 (À869/À863), EGR-1 (À564/À555) and TATAA box (À16/À12) were confirmed Novel SP3 binding site regulates IGFBP4 promoter Q Shen and P Singh AP-1 mutant (mut) BP4-luc vector was also similar to that of the full-length wt B4-luc vector (Figure 1d) , further validating the results in Figure 1c . These results suggest that positive regulatory element(s) other than AP-1 site exist in the 50 bp sequence from À897 to À847.
A novel promoter element is identified in the 50 bp fragment from À897 to À847
In order to identify the regulatory element(s) within the À897/À848 fragment, further deletion and replacement studies were conducted. The 50 bp fragment (À897/ À847) was divided into two halves and ligated to the truncated BP4 (À847/ þ 52)-luc vector. Ligation of the proximal 25 bp fragment from À872 to À848 resulted in almost complete recovery of the promoter activity, suggesting that positive regulatory element(s) were present within the proximal (À872/À848), but not in the distal (À897/À873) 25 bp sequence (Figure 1e ). Once again addition of either the wt or the AP-1 mut 25 bp fragment (À872/À848) resulted in an almost complete recovery of the promoter activity (Figure 1e ). These results validate that the AP-1 site is not involved directly in the positive regulation of the BP4 promoter activity. To identify the potential regulatory elements, we mutated the proximal 25 bp fragment (À872/À848) in a step-wise manner, downstream of the AP-1 site as shown in Figure 1e , and ligated the mut 25 bp fragments to the truncated BP4 (À847/ þ 52)-luc vector. Mutation of designated Site A (À861/À855), at the 3' end of AP-1 site (Site A mut) (Figure 1e ), resulted in significant reduction of promoter activity on days 6 and 8. On the other hand, mutation of 7 bp at the 3 0 distal end (Site B mut) had no significant effect on the activity of the promoter, suggesting the presence of a binding element (TGCTGCA) at À861/À855 within the BP4 promoter. Mutation of both the AP-1 site and the newly identified 3 0 element (AP-1 þ Site A mut) resulted in reducing promoter activity similar to that observed with Site A mut (Figure 1e ), suggesting that the newly identified element (Site A), and not the AP-1 binding site, was required for upregulation of the BP4 promoter activity. 
With reference to the CAP site.
b Published consensus sequence. AP-1 factor, junD, binds to the AP-1 site within the BP4 promoter
We first verified that the antibodies used in our studies against the AP-1 factors were functional and effective in either significantly reducing or supershifting the binding of control NE samples (from 3T6, 3T3SR and Jurkat cells) to the control AP-1 probe (Figure 3a) . We then examined the binding of CaCo2 NE to the wt 25 bp probe. Only anti-JunD Ab supershifted the proteins in band a bound to the wt 25 bp probe (Figure 3b ). The binding in band a was also reduced (but not supershifted) in the presence of anti-JunB Ab; all other antibodies had no significant effect on the binding of the proteins to any of the bands.
Mutation of the AP-1 site resulted in reduced binding to both a and b bands (Figure 3c ), suggesting the possibility that factors other than AP-1 proteins may also be binding the AP-1 site since anti-JunD Ab only supershifted the proteins in band a with no effect on proteins in band b (Figure 3b, c) . To confirm the specificity of anti-JunD-Abs, supershift analysis was conducted with the AP-1 mut probe (Figure 3c ). Mutation of AP-1 site resulted not only in the loss of binding to a and b protein bands but also resulted in the loss of any supershifted bands in the presence of antiJunD Abs (lanes 5-8 in Figure 3c ), supporting the specificity of binding of JunD factors in the NE of CaCo2 cells. In general, the binding to bands a-d and In panels c and d, EMSAs were performed using either the wt or mut 25 bp double-strandard (ds) oligonucleotide probes (À878/À848) in the presence of NE from 80-90% confluent CaCo2 cells. The mut 25 bp probes used in these studies are described at the bottom of Figure 1e . Representative autoradiographs from three to five separate experiments with wt or mut probes are shown in (c,d). Protein bands bound to the 25 bp probes are labeled as a-e bands. The band b sometimes appeared as a doublet (b1, b2). Equal amount of NE and labeled probes were loaded in each lane Novel SP3 binding site regulates IGFBP4 promoter Q Shen and P Singh especially a and b, were significantly enhanced in the presence of NE from day 10 CaCo2 cells compared to that from day 6 samples (Figure 3c) . In parallel studies, we have observed that the levels of endogenous AP-1 factors, including JunD, significantly increase during later days of cell culture (days 7-10) as the cells are increasingly differentiating (Shen et al., 1998a) , which may explain the enhanced binding observed with day 10 samples, especially to the a and b bands (Figure 3c ). The functional role of JunD binding to the AP-1 site need to be further investigated in the future.
Sp3-like proteins bind the newly identified cis element in the BP4 promoter
There is increasing evidence in literature that suggest that Sp-like proteins bind GC-rich areas in the promoter of IGF binding proteins (Gao and Tseng 1996) . We therefore decided to examine the possibility that Sp proteins may be binding the novel regulatory element that was identified in the experiments presented in Figures 1-3 . As a control, a consensus Sp1 probe was used in EMSA with NE from Hela cells, and antibodies against Sp1 and Sp3 supershifted and/or reduced the binding as shown in Figure 4a . The binding of NE from Hela cells to the wt 25 bp probe surprisingly was supershifted only in the presence of Sp3 antibody, but not Sp1 antibody (Figure 4b) . Similarly, in EMSA experiments with NE from CaCo2 cells, anti-Sp3-Ab was most effective in supershifting the proteins in band d, while the effects were minimal with anti-Sp1 Ab (Figure 4c ). Importantly, mutation of the AP-1 site had no effect on the effectiveness of anti-Sp3-Ab in supershifting proteins in band d (Figure 4c Figure 4d ) and an absence of any supershifted bands in the presence of anti-Sp3-Ab (lane 6, Figure 4d ). The results with the mutant probes presented in Figure 4b , c and d thus indicated that the newly discovered binding site in all probability represents a novel Sp3 binding site in the distal hBP4 promoter.
Sp3, but not Sp1 protein, generated by in vitro translation, binds to the novel Sp3 binding site
In order to establish that Sp3 protein can directly bind the newly identified Sp3 binding site in the human BP4 promoter, without interacting with coactivators or integrator proteins, we generated recombinant Sp1 and Sp3 protein by in vitro translation as described in Materials Methods. Sp1 and Sp3 proteins, thus generated, were verified by Western immunoblot analysis as shown in Figure 5a . Sp3 and Sp1 proteins were used in EMSA and supershift assays to confirm the binding of Sp3 proteins to the novel Sp3 site. The recombinant Sp3 protein was determined to specifically bind the 25 bp wt probe in an EMSA (lanes 2-4, Figure 5b ). In contrast, Sp3 protein did not bind the mutant 25 bp probe that was mutated at the novel Sp3 binding site (Site A mutant) (lanes 3 and 4, Figure 5b ). The specificity of the binding of recombinant Sp3 to the novel Sp3 site in the 25 bp wt probe was further confirmed in competition experiments, wherein increasing concentrations of unlabeled 25 bp wt probe were effective in displacing the binding of Sp3 to the labeled 25 bp wt probe; increasing concentrations of the Site A mutant probe, however, were ineffective ( Figure 5c ). Sp3, bound to 25 bp wt probe in an EMSA could be supershifted in the presence of anti-Sp3 antibody (lane 3, Figure 5d ), but anti-Sp1 antibody had no effect (lane 5, Figure 5d ). Both antiSp1 and anti-Sp3 antibodies were ineffective in supershifting any bands bound to the Site A mutant probe (Figure 5e ), further confirming that the wt Sp3 binding site was required for binding the Sp3 protein. Unlike Sp3, we did not measure any significant binding of recombinant Sp1 to either the 25 bp wt probe (Figure 5d ) or the Site A mutant probe (Figure 5e ), confirming the possibility that the newly discovered binding site in the human BP4 promoter represents a novel Sp3 binding site. These studies also suggest that Sp3 can directly bind the human BP4 promoter, in the absence of all other binding partners.
Functional role of the Sp3 protein and its binding site within the Bp4 promoter is confirmed in DS2 Schneider insect cells
To further examine the functional role of Sp3 factor and the identified Sp3 binding site within the BP4 promoter, we compared the activity of either the wt promoter-luc vector or the mutant promoter-luc vector, which was mutated at the Sp3 binding site, in an insect cell line that is not known to express endogenous Sp-like proteins. The basal activity of the wt and the Sp3 mutant promoters was similar in the insect cells (Figure 6a ). The insect cells were transfected with the Sp3 expression vector to examine the effect on promoter activity. Overexpression of the Sp3 protein significantly upregulated the activity of the wt promoter-reporter vector, without any significant effects on the activity of the Sp3 mutant promoter-reporter vector (Figure 6b ). Transfection with the control vectors had no effect on the activity of either the wt or mut BP4-luc vectors (Figure 6a, b) . These results support the conclusion that Sp3 and its identified binding site in the distal BP4 promoter cooperatively upregulate the activity of the BP4 promoter in CaCo2 cells.
Discussion
In previous studies, we had measured a significant upregulation of BP4 promoter in response to c-Jun overexpression (Shen et al., 1998a; Shen et al., 1998b) , suggesting that the single AP-1 site, contained within the functional human BP4 promoter sequence, may play a role in upregulating BP4 promoter activity. The results of our current study, however, suggest for the first time that the AP-1 binding site does not play a significant role in the upregulation of the BP4 promoter activity in a human colon cancer cell line, CaCo2 cells. A step-wise mutation of the promoter led us to identify a novel 7 bp sequence at the 3 0 end of the AP-1 site, which was critically required for upregulating the BP4 promoter activity. This positive element (À861/À855) did not demonstrate significant homology with any of the known binding sites based on computer search of the available databases. There is growing evidence in literature that suggests an important role of Sp1/3 proteins in regulating the expression of IGFBPs (Hagen et al., 1992; Kingsley and Winoto, 1992; Boisclair et al., 1993; Lania et al., 1997; Tseng et al., 1997; Kutoh et al., 1999; Suske, 1999) . We therefore examined the possibility that the positive element may represent a novel Sp1/Sp3 binding site. Of all the Sp1 family of proteins, only Sp3 was determined to specifically bind this novel site. Mutation of the novel site in the 25 bp BP4 promoter probe resulted in the loss of binding to both the purified Sp3 protein and to the Sp3-like proteins in the NE of CaCo2 cells. Thus, the newly identified binding site (5 0 TGCTGCA 3 0 ) may represent a novel Sp-3 binding site. Sp family of proteins consist of Sp1, Sp2, Sp3 and Sp4, which are expressed ubiquitously (Hagen et al., 1992; Kingsley and Winoto, 1992; Supp et al., 1996) , and are known to be involved in the regulation of tissueand cell-specific gene expression (Lania et al., 1997) . The Sp proteins recognize GC-box (GGGGCGGGG) and the related GT/CACCC-box (GGTGTGGGG), which are required for the expression of various tissue-specific genes (Suske 1999) . No consensus GC-box (Sp-1 binding site), however, was found in the hIGFBP4 gene ( Table 2 ). The novel Sp3 binding sequence of 5 0 -TGCTGCA-3 0 , located at À861/À855 in the IGFBP4 promoter has, to the best of our knowledge, not been reported. More than 30 binding sequences have been identified for the Sp family of proteins; all of them are GC-rich sequences that range from 6-13 bp (Boisclair et al., 1993; Kao et al., 1997; Suske, 1999; Liu et al., 2000; Maor et al., 2000; Zhu et al., 2000) . In a recent report, a 13 bp sequence on the Nkx2.1 promoter region was identified to be transactivated by Sp1 and Sp3 factors ; the sequence 5 0 -GCCTCCGGGAGGC-3 0 was specifically bound by Sp1 and Sp3, and an H441 cell nuclear factor.
The newly identified Sp3 binding site in current study appears in the regulatory regions of many genes that are involved in energy and lipid metabolism, cellular mobility, stress response and signal transduction pathways, membrane trafficking, cell cycle regulation, differentiation and cancer. Some of these genes include Cox7c, hepatic dihydroldiol dehydrogenase, lactate dehydrogenase, EGF receptor, N-myc, gp38k, a-tropomyosin, calmodulin, profilin, clusterin, second-MEF2-lok protien-1, VPS35, cyclin G1, DRG1, BLCAP and BCAS2 (Praz et al., 2002) . It is speculated that Sp3 binding site(s), together with Sp3 factor, confer Sp3-specific regulation of target gene expression. Therefore, further studies are warranted for examining the biological role of the specific binding sites that preferentially bind Sp3. Different Sp proteins may differentially effect the transcription of specific genes (Nielsen et al., 1998) , which may be mediated by differences in the binding Each bar represents mean SEM of 2-4 measurements in a single experiment and is representative of three experiments. Overexpression of pPacSp1 vector, on the other hand, demonstrated no effect on the activity of either the wt or mut BP4 promoter-luc vector (data not shown).
Novel SP3 binding site regulates IGFBP4 promoter Q Shen and P Singh affinity of the Sp1 family of proteins for binding the multiple Sp1 site(s) (Pan et al., 2000) . The latter may provide a means for fine tuning the tissue-and cellspecific regulation of gene expression. Multiple Sp1/3 sites are located in the distal promoter region of IGFBP1 gene. Binding of Sp3 to these sites results in tissue-specific expression of IGFBP1 (Gao and Tseng, 1996; Tseng et al., 1997) . Sp1 site(s) are also present in the promoter of rat and murine IGFBP2 gene (Boisclair et al., 1993; Kutoh et al., 1999) . Three clustered Sp1 sites were required for regulation of IGFBP2 promoter activity in BRL-3A cells (Boisclair et al., 1993) . Sp1 consensus binding sequences are present within the promoter of IGFBP3 gene and may be important in mediating regulatory effects of IGF-I and forskolin on IGFBP3 promoter activity in mammary epithelial cells (Cohick et al., 2000) . Two GC-rich sequences at À559/ À553 and À72/À64 were reported to be important for 17 b-estradiol-induced transactivation of hBP4 promoter in human breast cancer MCF-7 cells; Sp1 protein was found to be bound to the sequence 5 0 -GGGGCGGG-3 0 (Qin et al., 1999) . Several Sp1 variant sites and a novel Sp3 binding site were identified in the hBP4 promoter in the current study, and an important role of Sp3 in upregulating BP4 promoter activity was confirmed in experiments with insect cells. These findings suggest that Sp factors may be critically required for regulating gene expression of several IGFBPs including IGFBP4. Based on our studies so far (Dai et al., 1997; Singh et al., 1996 , and current studies), we hypothesize that Sp3 plays an important role in differentiation of CaCo2 cells via upregulating the expression of IGFBP4 gene during days 7-11 of cell culture. Presence of low levels of Sp1 in breast cancer cells, MCF-7, was reported to repress transcriptional activity of TFGb receptor type II gene resulting in increased tumorigenicity of the cells . It is similarly possible that Sp3 is expressed at low levels in aggressively growing colon cancer cells, resulting in loss of transcriptional activation of BP4 gene that may translate into the observed loss of differentiation of these cells; the latter possibility will be examined in future studies. In parallel studies, we measured a significant increase in the relative concentrations of Sp3 in CaCo2 clones overexpressing c-Jun (Shen and Singh 2001) , suggesting an indirect mechanism by which AP-1 factors may be upregulating the activity of BP4 promoter in CaCo2 cells.
In summary, we have identified a novel element of 7 bp (5 0 TGCTGCA3 0 ) at À861/À855 nt, which is required for upregulating the activity of BP4 promoter in CaCo2 cells. Sp3 was found to be specifically bound to this novel binding site. In related studies, we measured significant expression of almost all AP-1 factors and Sp1 and Sp3 proteins in CaCo2 cells, which were expressed increasingly during days 5-12 of cell culture associated with increasing differentiation of the cells (unpublished data). Importantly, c-Jun and Sp3 were expressed in a parallel manner that correlated with the growth and differentiation pattern of CaCo2 cells (unpublished data). It is speculated that the increasing availability of c-Jun in differentiating CaCo2 cells may increase the expression of Sp3, resulting in upregulation of BP4 gene expression in CaCo2 cells, thus enhancing the differentiation potential of cells in vitro.
Materials and methods
Materials
Reagent grade chemicals were purchased from Sigma. Oligonucleotides for mutant constructs were synthesized by Genemed Synthesis Inc. (South San Francisco, CA, USA). Specific antibodies against Sp1-4 and AP-1 factors were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and Geneka Biotechnology Inc. (Montreal, Canada). Endonucleases, T4 polynucleotide kinase and T4 ligase were purchased from New England Biolabs (Beverly, MA, USA). The [g-32 P]ATP was purchased from ICN (Costa Mesa, CA, USA).
Cell culture
CaCo2 cells were obtained from Dr Jing Yu, Tufts School of Medicine (Boston, MA, USA). Exponentially growing cells were seeded at 2 Â 10 5 cells per 35 mm cell culture dishes, and cultured in growth medium (DMEM supplemented with 2 mM glutamine, 1 mM sodium pyruvate and 25 mM high glucose, and 10% heat-inactivated FBS) as described previously (Singh et al., 1994a (Singh et al., , b, 1996 Dai et al., 2001) 
Transient transfection of CaCo2 cells
CaCo2 cells in 35 mm culture dishes were transfected with 2.5 mg of the indicated plasmids on days 3-10 of cell culture by calcium phosphate precipitation method, as described previously (Dai et al., 1997; Singh et al., 1998) . Cells were cotransfected with an SV40 b-galactosidase expression vector (pSV-b-gal, Promega) to normalize results for efficiency of transfection on different days of cell culture. At 48 h after transfection, cells were collected and lysed for measuring luc and b-gal activities. Cells were transfected with either the fulllength, truncated or mutated BP4 promoter-luc expression vectors, in the presence or absence of c-Jun expression vector (gift from Dr S Widen, UTMB at Galveston). Control cells were transfected with the control empty vectors.
Transient transfection of insect cells
The DS2 Schneider insect cell line was purchased from ATCC, Manassas, VA. The cells were maintained in Cellgro DS2 media (Cellgro, Henderson, VA) with 20 mM glutamine, 5% FBS and 1% gentamycin. Cells (8 Â 10 5 ) were seeded in sixwell plates and transfected with the plasmids as described above for CaCo2 cells. pPacSp1 and pPacSp3 expression vectors were from Dr G Suske (Institut fuˆr Molekularbiologie Tumorrforschung, Germany).
Luc and b-gal activity assays
Luc and b-gal activities were measured in the cell lysates as previously described (Dai et al., 1997; Dai et al., 2001) .
Confirmation and verification of the promoter sequence of BP4 in luc reporter vector PGl-2 BP4 promoter-reporter, BP4-S-pGL (Dai et al., 1997) , was used in the present studies. The BP4-S-pGL vector was sequenced before deletion constructs were made. The obtained sequence was aligned and compared with the sequence previously published (Dai et al., 1997) . Some minor differences in the nt sequences were noted and are indicated in Table 1 . The sequenced BP4-S-pGL vector was renamed BP4 (À1250/ þ 52)-luc.
Generation of deletion constructs of BP4 (À1250/ þ 52)-luc vector for examining the role of AP-1 binding site
The plasmid BP4 (À1250/ þ 52)-luc was used as template for generating the deletion fragments of interest. Sense primers used for creating promoter-luc constructs that either contained or lacked the wt AP-1 binding site were (1) BP4-897/878: 5 0 GCC TCC AAA AGT GCT GAC AT3 0 and (2) BP4-847/ 828: 5 0 CAA ATC CTT CAC TGC CAT CT3 0 , respectively. A common 3 0 anchor primer (BP4 þ 33/52: 5 0 CTC GAG GAC TGG GCG CGG GC3 0 ) was used for polymerase chain reaction (PCR) amplification. The PCR amplifications were carried out in 50 ml volume of 1 Â PCR buffer (Promega), 1.5 mM MgCl 2 , 200 mM dNTPs mix, 3 0 and 5 0 primers each 20 pmol, template DNA 15 ng, and 1.25 U of Taq DNA polymerase. The reaction mixtures were subjected to 25 cycles in a Hybaid OmniGene PCR cycler (Hybaid, Potomac, MD, USA): 941C, 1 min; 551C, 1 min; 721C, 1 min 30 s; followed by a final extension at 721C for 10 min. Aliquots (10 ml) of the PCR products were electrophoresed in 1% agarose gel and visualized by ethidium bromide staining. The PCR products were subcloned into PCR2.1 vector using the TOPO TA Cloning Kit (Invitrogen, Carlsbad, CA, USA). Positive clones were selected by antibiotic selection. Inserts were sequenced for verifying the fragments and their orientation. Fragments of BP4 promoter DNA were released from the PCR2.1 vectors by KpnI and XhoI endonucleases. The released fragments were religated into the promoterless luc reporter vector pGL-2 Basic (Promega, Madison, WI, USA). The truncated plasmids were named BP4 (À897/ þ 52)-luc and BP4 (À847/ þ 52)-luc. Sequence of the deleted promoter fragments in pGL-2 Basic luc reporter vector was reverified at both cloning sites. The constructs were used to transform TOP10F' competent cells (Invitrogen, Carlsbad, CA, USA), followed by large-scale preparation, and purification by equilibrium centrifugation in CsClethidium bromide gradients.
Creation of full-length, Ap-1 mutant, Bp4 promoter reporter Two sets of primers were designed according to the confirmed promoter sequence. The sequences of the primers used are listed below: (1) 5 0 GGT ACC GTT CAC CGT GCT AGC AGG3'; (2) 5 0 CTC GAG GAC TGG GCG CGG GC3 0 ; (3) 5 0 GAA TTC CCG CTG CAG GCC CCT CAA ATC CTT C3 0 ; (4) 5 0 GAA TTC GCA CCT TGT AAT GTC AGC ACT TTT GG3 0 . Primers 1 and 2 were used to amplify the distal fragments of the promoter from À1250 to À866, with KpnI site on 5 0 end and EcoRI site on 3 0 end; primers 3 and 4 were used to amplify the proximal fragments from À865 to þ 52, with EcoRI site on 5 0 end and XhoI site on 3 0 end. The PCR products were subjected to digestion by EcoRI to form sticky ends, followed by ligation of the two fragments with T4 ligase. The AP-1 site was mutated at 4 bp from 5 0 TGAGTCA3 0 to 5 0 CGAATTC3 0 . The fulllength AP-1 mutant BP4 promoter fragment was subcloned into pGL-2 Basic promoterless reporter at the KpnI/XhoI cloning sites. Sequence of the mutant was confirmed by DNA sequencing. The mutant was termed BP4 (AP-1mut)(À1252/ þ 52)-luc.
Ligation of the 50 bp fragments (À897/À848) and 25 bp fragments (À872/À848) to the BP4 (À847/ þ 52)-luc vector and construction of promoter mutants The BP4 (À847/ þ 52)-luc construct had a short linker fragment with multiple cloning sites for SacI, BamHI, SpeI, BstXI and EcoRI at the 5 0 end of the promoter. The BP4 (À847/ þ 52)-luc vector was digested and linearized with SacI and Spel and purified for subsequent cloning. Sense and antisense oligonucleotide fragments, complementary to each other for the entire 50 bp sequence (À897/À848), with wt or mutated AP-1 site (from 5 0 TGAGTCAC3 0 to 5 0 CTCTCTGT3 0 ), were designed to contain either SacI or XhoI sites at the 5 0 end and SpeI site at the 3 0 end. The created 50 bp dsDNA fragments were ligated to the linearized BP4 (À847/ þ 52)-luc vector. Positive clones were picked up after transformation of TOPO10F-. The clones were verified by restriction map analysis. Plasmids were prepared for transfection experiments.
Preparation of crude nuclear extract
Crude NE were prepared from CaCo2 cells on the indicated days of cell culture by methods described by Dignam (1990) . The protein concentrations were measured by the BCA Protein Assay Reagent (Pierce, Rockford, IL, USA).
In vitro translation of Sp1 and Sp3 proteins
Recombinant Sp1 and Sp3 proteins were translated in vitro using a TNT s Coupled Reticulocyte Lysate Kit (Promega, Madison, WI, USA), as per instructions provided by the manufacturer. The in vitro expression plasmids (pBS-Sp1-fl and pSPT18/Sp3fl) were obtained from Dr Guntram Suske (Institut fur Molekularbiologie und Tumirforschung PhilippsUniversitat, Marburg, Germany). Both expression vectors were used as templates to translate Sp1 and Sp3 in vitro, respectively. Briefly, the expression of Sp proteins was carried out in a reaction tube containing 25 ml of reticulocyte lysate, 2 ml reaction buffer, 1 ml of complete amino-acid mixture, 1 ml of RNAsin, 1 mg of template plasmid and 1 ml of T7/T3 polymerase; ddH 2 O was added to attain a final volume of 50 ml. The mixture was incubated at 301C for 90 min, and an aliquot (5 ml) of the reaction, along with Hela NE, was separated eletrophoretically on 10% SDS page and processed for Western immunoblot analysis with anti-Sp1 and anti-Sp3 antibodies to verify the synthesis of the Sp proteins. The reaction mixtures were confirmed to contain the recombinant Sp proteins, wherein B1 ml of the reaction mixture was equivalent to Sp proteins present within 4 mg of the Hela NE. The Sp proteins thus generated were used in EMSA as described above.
EMSA
EMSA was performed with a Gel Shift Assay Systems kit from Promega (Madison, WI, USA) or from Geneka Biotechnology Inc. (Montreal, Canada), as described previously (Dai et al., 1997) .
Supershift assay
Supershift assays were performed with the Nushift Kit from Geneka Biotechnology Inc. (Montreal, Canada) . Probes were labeled with [g-32 P]ATP with T4 polynucleotide kinase, and purified using G-50 columns. Nuclear proteins in binding buffer were mixed with stabilizing solution and specific antibodies for either c-Jun, JunB, JunD, c-Fos, FosB or Sp1-4 added. After 20 min of incubation at 4-81C, the labeled probes were added to the preincubated nuclear protein/ antibody mix and incubated for another 20 min. Samples were then loaded onto a 5% polyacrylamide gel in TBE or TGE (Tris-Glycine-EDTA) electrophoresis buffer prepared as per the manufacturer's instruction and electrophoresed at 240 V for 2 h. The gels were dried on Whatman 3MM paper and exposed to Kodak film with intensifying screens overnight.
Abbreviations AP-1, activator protein 1; b-gal, b-galactosidase; bp, base pair; BP4, Insulin-like growth factor binding protein 4; ds, double stranded; EMSA, electrophoretic mobility shift assay; IGF, insulin-like growth factor; IGFBP, IGF binding protein; luc, luciferase; mut, mutant; NE, nuclear extract; nt, nucleotide; PCR, polymerase chain reaction; Sp, specificity protein; wt, wild type.
